ZetrOZ is revolutionizing the medical therapeutic industry with its proprietary technology including the recently introduced sam sustained acoustic medicine www.samrecover.com and UltrOZ www.ultroz.com, miniature wearable ultrasound devices for accelerated recovery and pain management. The innovative non-invasive therapeutic technologies have been shown to be more efficient, more portable, and more economically viable than any ultrasound systems presently available and are currently the world's smallest and strongest ultrasound therapy systems. The sam device addresses the growing demand for non-pharmaceutical and bio-regenerative alternatives to typical pharma-based pain treatments in the approximately $62 billion U.S. pain management market. Early adopters of sam include physical therapists, athletic trainers and athletes for improved recovery of overuse injuries such as tendonopathies and muscle strains. ZetrOZ is also known for developing the first swallowable ultrasound pill with Massachusetts Institute of Technology and is supported by the U.S. National Institutes of Health and U.S. Department of Defense.
Date | Amount | Type | Investors | Valuation |
---|---|---|---|---|
10/20/14 | $5,000,000 | Venture Debt |
Horizon Technology Finance | undisclosed |